SCHEMBL6741196

SCHEMBL6741196

C[C@@H](C[CH]C(=O)N[C@H]1CCN(S(=O)(=O)c2cc(Cl)c(OC3CCNCC3)c(Cl)c2)C1)C(N)=O

nearest known ligand 0.48

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
UTS2R Q9UKP6 12/20 0.48
HTR1A P08908 1/20 0.35
CYP2D6 P10635 1/20 0.35
DRD2 P14416 1/20 0.35
HTR1D P28221 1/20 0.35
HTR2C P28335 1/20 0.35
HTR1F P30939 1/20 0.35
HTR2B P41595 1/20 0.35
HTR6 P50406 1/20 0.35
CYP3A43 Q9HB55 1/20 0.35
TGM2 P21980 4/20 0.34
NPC1 O15118 2/20 0.34
RAB9A P51151 1/20 0.34
ATM Q13315 1/20 0.34
POLB P06746 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6739732 0.96 UTS2R (0.46) UTS2RTGM2NPC1POLBSMN1; SMN2
SCHEMBL6741280 0.90 UTS2R (0.55) UTS2RHTR1ACYP2D6DRD2HTR1D
SCHEMBL6741880 0.86 UTS2R (0.44) UTS2RTGM2POLBSMN1; SMN2
SCHEMBL6744733 0.86 UTS2R (0.44) UTS2RTGM2POLBSMN1; SMN2
SCHEMBL6744780 0.84 UTS2R (0.61) UTS2RHTR1ACYP2D6DRD2HTR1D
SCHEMBL6742625 0.84 UTS2R (0.61) UTS2RHTR1ACYP2D6DRD2HTR1D
SCHEMBL6093542 0.83 UTS2R (0.37) UTS2RTGM2SMN1; SMN2
SCHEMBL6741197 0.83 UTS2R (0.52) UTS2RHTR1ACYP2D6DRD2HTR1D
SCHEMBL6093947 0.83 SMN1; SMN2 (0.44) UTS2RHTR2CTGM2POLBSMN1; SMN2
SCHEMBL6741630 0.81 UTS2R (0.46) UTS2RSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040152692-A1 Urotensin antagonist; therapy for congestive heart failure; antiischemic agents; cardiovascular disorders; strokes; hypotensive agents; respiratory system disorders; restenosis; antiinflammatory agents; psychological disorders SMITHKLINE BEECHAM CORPORATION 2004-08-05 US claimed
US-20040152692-A1 Urotensin antagonist; therapy for congestive heart failure; antiischemic agents; cardiovascular disorders; strokes; hypotensive agents; respiratory system disorders; restenosis; antiinflammatory agents; psychological disorders SMITHKLINE BEECHAM CORPORATION 2004-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040152692-A1 Urotensin antagonist; therapy for congestive heart failure; antiischemic agents; cardiovascular disorders; strokes; hypotensive agents; respiratory system disorders; restenosis; antiinflammatory agents; psychological disorders UTS2R, PLAUR, SERPINE1 UTS2R 1/4885HTR1A 769/4885CYP2D6 4600/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.